Results 101 to 110 of about 12,113 (164)

The Endocannabinoid System in Neuropsychiatric Disorders: Mechanisms, Dysregulation and Therapeutic Potential. [PDF]

Biomedicines
Mušić T, Turnšek TL.
europepmc   +1 more source

Cardiovascular Effects of Cannabidiol: From Molecular Mechanisms to Clinical Implementation. [PDF]

Int J Mol Sci
Urlić H, Kumrić M, Pavlović N, Dujić G, Dujić Ž, Božić J.   +5 more
europepmc   +1 more source

Advances in neuropsychiatry: From objective diagnostics to mechanism-based therapeutics. [PDF]

Neurotherapeutics
Pieper AA, Lee FS.
europepmc   +1 more source

Changes in phosphoethanolamine during the postpartum period and its association with depression. [PDF]

Fukushima J Med Sci
Kanno A, Yoshida-Komiya H, Yamaguchi A, Nishigori H, Goto A, Fujimori K.   +5 more
europepmc   +1 more source

Targeting Pain and Depression in Alzheimer's Disease: Translational Insights and Emerging Treatments. [PDF]

Pharmaceuticals (Basel)
Costachescu I, Stanciu GD, Gogu RM, Tamba BI.   +3 more
europepmc   +1 more source

Targeted lipidomics dataset of central nervous system and plasma from mice with experimental autoimmune encephalomyelitis. [PDF]

Data Brief
Lötsch J, Tegder I, de Bruin N, Thomas D, Geisslinger G.   +4 more
europepmc   +1 more source

Potential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review. [PDF]

Front Vet Sci
Medina FJ, Torres CG.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anandamide: an update

Fundamental & Clinical Pharmacology, 2006
AbstractEndocannabinoid system has attracted the researchers to investigate into its ever fascinating roles governing many of the physiological functions in the human body. The prime endogenous cannabinoids are arachidonoylethanolamide also called anandamide and 2‐arachidonoylglycerol.
K, Smita, V, Sushil Kumar, J S, Premendran   +2 more
openaire   +2 more sources